In vivo toxicity and biodistribution of intravenously administered antibiotic-functionalized gold nanoparticles
Abstract The utilization of engineered gold nanoparticles (GNPs) in biomedical applications is experiencing rapid growth owing to their reactive nature and remarkable flexibility. However, despite these advantages, concerns persist regarding their in vivo biocompatibility and cytotoxicity. This study aimed to assess the toxicity, biodistribution, and excretion pathways of GNPs functionalized with various antibiotics, namely, ciprofloxacin, levofloxacin, cefotaxime, and ceftriaxone, using a mouse model. Following intravenous administration, the nanostructures induced an increase in serum enzyme levels and histological abnormalities in the liver, indicating potential hepatotoxic effects. Analysis of organ distribution revealed accumulation primarily in the liver and spleen, with concentrations gradually decreasing 168-h post-administration. Fecal excretion was identified as the primary route of elimination, with a smaller portion excreted via urine. Among the different nanostructures evaluated, those functionalized with levofloxacin (LEV-NP) exhibited minimal organ toxicity and a high clearance rate. Additionally, LEV-NP, with a size of approximately 12 nm, demonstrated superior drug particle stability and lower red blood cell hemolytic activity compared to other nanostructures..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Gold bulletin - 56(2023), 4 vom: Dez., Seite 209-220 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vasappa, Rashmi Kanugodu [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Biodistribution |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s13404-024-00343-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05554696X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05554696X | ||
| 003 | DE-627 | ||
| 005 | 20240417064736.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240417s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13404-024-00343-9 |2 doi | |
| 035 | |a (DE-627)SPR05554696X | ||
| 035 | |a (SPR)s13404-024-00343-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 620 |a 660 |q VZ |
| 084 | |a 51.54 |2 bkl | ||
| 084 | |a 58.41 |2 bkl | ||
| 084 | |a 38.30 |2 bkl | ||
| 100 | 1 | |a Vasappa, Rashmi Kanugodu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vivo toxicity and biodistribution of intravenously administered antibiotic-functionalized gold nanoparticles |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract The utilization of engineered gold nanoparticles (GNPs) in biomedical applications is experiencing rapid growth owing to their reactive nature and remarkable flexibility. However, despite these advantages, concerns persist regarding their in vivo biocompatibility and cytotoxicity. This study aimed to assess the toxicity, biodistribution, and excretion pathways of GNPs functionalized with various antibiotics, namely, ciprofloxacin, levofloxacin, cefotaxime, and ceftriaxone, using a mouse model. Following intravenous administration, the nanostructures induced an increase in serum enzyme levels and histological abnormalities in the liver, indicating potential hepatotoxic effects. Analysis of organ distribution revealed accumulation primarily in the liver and spleen, with concentrations gradually decreasing 168-h post-administration. Fecal excretion was identified as the primary route of elimination, with a smaller portion excreted via urine. Among the different nanostructures evaluated, those functionalized with levofloxacin (LEV-NP) exhibited minimal organ toxicity and a high clearance rate. Additionally, LEV-NP, with a size of approximately 12 nm, demonstrated superior drug particle stability and lower red blood cell hemolytic activity compared to other nanostructures. | ||
| 650 | 4 | |a Gold nanoparticles |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Levofloxacin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Biodistribution |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Excretion |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug delivery |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Multidrug resistance |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Mohan, Darshini Shivamogga |e verfasserin |4 aut | |
| 700 | 1 | |a Mutalik, Srinivas |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnaswamy, Manjunatha Bukkambudhi |e verfasserin |4 aut | |
| 700 | 1 | |a Srinivasalu, Anil Kumar Honnali |e verfasserin |4 aut | |
| 700 | 1 | |a Suryanarayana, Mukunda |e verfasserin |4 aut | |
| 700 | 1 | |a Muddappa, Vidya Shimoga |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gold bulletin |d Springer International Publishing, 1971 |g 56(2023), 4 vom: Dez., Seite 209-220 |w (DE-627)SPR031595103 |w (DE-600)2138735-7 |x 2190-7579 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2023 |g number:4 |g month:12 |g pages:209-220 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13404-024-00343-9 |m X:VERLAG |x 0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-GGO | ||
| 936 | b | k | |a 51.54 |q VZ |
| 936 | b | k | |a 58.41 |q VZ |
| 936 | b | k | |a 38.30 |q VZ |
| 951 | |a AR | ||
| 952 | |d 56 |j 2023 |e 4 |c 12 |h 209-220 | ||